Invesco’s scPharmaceuticals SCPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-24,167
| Closed | -$137K | – | 3847 |
|
|
2025
Q3 | $137K | Sell |
24,167
-1,712
| -7% | -$8.77K | ﹤0.01% | 3636 |
|
|
2025
Q2 | $98.6K | Sell |
25,879
-2,823
| -10% | -$8.76K | ﹤0.01% | 3652 |
|
|
2025
Q1 | $75.5K | Buy |
28,702
+1,088
| +4% | +$3.54K | ﹤0.01% | 3664 |
|
|
2024
Q4 | $97.8K | Buy |
27,614
+6,073
| +28% | +$23.3K | ﹤0.01% | 3626 |
|
|
2024
Q3 | $98.2K | Sell |
21,541
-1,117
| -5% | -$5.4K | ﹤0.01% | 3625 |
|
|
2024
Q2 | $98.6K | Buy |
22,658
+9,955
| +78% | +$43.7K | ﹤0.01% | 3755 |
|
|
2024
Q1 | $63.8K | Sell |
12,703
-72
| -0.6% | -$403 | ﹤0.01% | 3784 |
|
|
2023
Q4 | $80.1K | Sell |
12,775
-14,769
| -54% | -$84.6K | ﹤0.01% | 3710 |
|
|
2023
Q3 | $196K | Buy |
27,544
+12,800
| +87% | +$101K | ﹤0.01% | 3598 |
|
|
2023
Q2 | $150K | Buy |
+14,744
| New | +$154K | ﹤0.01% | 3666 |
|
|
2021
Q2 | – | Sell |
-10,726
| Closed | -$71K | – | 4026 |
|
|
2021
Q1 | $71K | Buy |
10,726
+193
| +2% | +$1.32K | ﹤0.01% | 3800 |
|
|
2020
Q4 | $56K | Buy |
+10,533
| New | +$82.5K | ﹤0.01% | 3732 |
|
Invesco's SCPH Position: Q4 2025 in Review
Invesco sold out of scPharmaceuticals (SCPH) in Q4 2025, closing a stake of 24,167 shares — an estimated $137K sold.
Invesco first reported a position in SCPH in Q4 2020 and held it in 12 quarters. The position peaked at $196K in Q3 2023. 0 funds tracked by Wall St. Rank hold SCPH as of Q4 2025.
- Invesco reported no remaining scPharmaceuticals position as of Q4 2025 after selling out during the quarter.
- Invesco sold 24,167 scPharmaceuticals shares in Q4 2025, an estimated $137K.
- Invesco first reported a position in scPharmaceuticals in Q4 2020 and held it in 12 quarters.
- Invesco's scPharmaceuticals position peaked at $196K in Q3 2023.
- 0 funds tracked by Wall St. Rank held scPharmaceuticals as of Q4 2025.
Based on Invesco's 13F filing for Q4 2025, filed 19 Feb 2026.